ATE342719T1 - Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit - Google Patents

Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit

Info

Publication number
ATE342719T1
ATE342719T1 AT03785652T AT03785652T ATE342719T1 AT E342719 T1 ATE342719 T1 AT E342719T1 AT 03785652 T AT03785652 T AT 03785652T AT 03785652 T AT03785652 T AT 03785652T AT E342719 T1 ATE342719 T1 AT E342719T1
Authority
AT
Austria
Prior art keywords
rotigotine
parkinson
disease
treatment
iontophoretic administration
Prior art date
Application number
AT03785652T
Other languages
English (en)
Inventor
Hans-Michael Wolff
Johanna Aaltje Bouwstra
Gai Ling Li
Akhmad Kharis Nugroho
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE342719(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE342719T1 publication Critical patent/ATE342719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT03785652T 2002-12-02 2003-11-21 Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit ATE342719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026871A EP1426049B1 (de) 2002-12-02 2002-12-02 Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese

Publications (1)

Publication Number Publication Date
ATE342719T1 true ATE342719T1 (de) 2006-11-15

Family

ID=32309357

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02026871T ATE295726T1 (de) 2002-12-02 2002-12-02 Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
AT03785652T ATE342719T1 (de) 2002-12-02 2003-11-21 Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02026871T ATE295726T1 (de) 2002-12-02 2002-12-02 Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese

Country Status (24)

Country Link
US (1) US7632859B2 (de)
EP (2) EP1426049B1 (de)
JP (1) JP2006514937A (de)
KR (1) KR101168431B1 (de)
CN (1) CN100333723C (de)
AT (2) ATE295726T1 (de)
AU (1) AU2003294718B2 (de)
BR (1) BR0316947A (de)
CA (1) CA2505040C (de)
CY (1) CY1106256T1 (de)
DE (2) DE60204229T2 (de)
DK (2) DK1426049T3 (de)
ES (2) ES2239196T3 (de)
HK (2) HK1065706A1 (de)
IL (1) IL168387A (de)
MX (1) MXPA05005462A (de)
NO (1) NO335491B1 (de)
NZ (1) NZ540190A (de)
PL (1) PL219696B1 (de)
PT (2) PT1426049E (de)
RU (2) RU2339372C2 (de)
SI (2) SI1426049T1 (de)
WO (1) WO2004050083A1 (de)
ZA (1) ZA200503750B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (de) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
DE202008002377U1 (de) 2008-02-20 2009-06-25 Washtec Holding Gmbh Reinigungsvorrichtung
DE102008010223A1 (de) 2008-02-20 2009-08-27 Wash Tec Holding Gmbh Reinigungsvorrichtung
EP2281559A1 (de) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmazeutische Zusammensetzung enthaltend Rotigotin (Salze oder Na), insbesondere für Iontophorese
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
EP2559435A1 (de) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotin in der Behandlung von Hemineglekt, Schlaganfall und Defiziten nach einem Schlaganfall
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3145503A1 (de) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Verfahren zur anpassung der freisetzung eines wirkstoffs in einem transdermalen abgabesystem
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN109415335B (zh) * 2016-07-21 2020-06-05 山东绿叶制药有限公司 罗替戈汀山嵛酸酯及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
ATE84667T1 (de) * 1986-01-31 1993-02-15 Whitby Research Inc Hautpenetration verbessernde zusammensetzungen.
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5142044A (en) * 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5073544A (en) * 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US5118845A (en) * 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
DE3868866D1 (de) * 1987-11-20 1992-04-09 Erba Carlo Spa Ergolinderivate mit antiparkinsonwirkung.
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
DE3827561C1 (de) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
AU2514292A (en) * 1991-08-27 1993-03-16 Cygnus Therapeutic Systems Transdermal formulations for administering prazosin
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
EP0707465A4 (de) * 1993-07-08 1997-04-16 Cygnus Therapeutic Systems Monolithisches matrix transdermales abgabesystem
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
DE69429603T2 (de) * 1993-09-22 2002-08-14 Hisamitsu Pharmaceutical Co., Inc. Iontophoresematrix
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
HU228434B1 (en) * 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
JP3507437B2 (ja) * 1998-05-13 2004-03-15 シグナス， インコーポレイテッド 経皮サンプリング系のための収集アセンブリ
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
WO2000015108A1 (en) * 1998-09-17 2000-03-23 Cygnus, Inc. Press device for a gel/sensor assembly
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
WO2000074661A2 (en) * 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
DK1233763T3 (da) * 1999-11-29 2003-10-20 Lohmann Therapie Syst Lts Transdermale terapeutiske systemer med forbedret stabilitet og en fremgangsmåde til deres fremstilling
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
BRPI0312007B1 (pt) * 2002-06-25 2015-04-14 Acrux Dds Pty Ltd Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
EP1708706A1 (de) * 2004-01-22 2006-10-11 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahme-hemmer und einem dopaminagonisten
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss

Also Published As

Publication number Publication date
EP1426049A1 (de) 2004-06-09
PT1567146E (pt) 2007-01-31
RU2478383C2 (ru) 2013-04-10
AU2003294718A1 (en) 2004-06-23
DE60309203T2 (de) 2007-08-23
KR101168431B1 (ko) 2012-07-25
DK1426049T3 (da) 2005-08-22
DE60204229T2 (de) 2006-02-02
EP1567146B1 (de) 2006-10-18
KR20050086886A (ko) 2005-08-30
SI1426049T1 (en) 2005-08-31
RU2005114749A (ru) 2006-01-20
NO335491B1 (no) 2014-12-22
WO2004050083A1 (en) 2004-06-17
DE60204229D1 (de) 2005-06-23
IL168387A (en) 2009-05-04
CA2505040C (en) 2012-10-16
DE60309203D1 (de) 2006-11-30
PL377575A1 (pl) 2006-02-06
CN1720041A (zh) 2006-01-11
ES2273062T3 (es) 2007-05-01
US20040116537A1 (en) 2004-06-17
EP1426049B1 (de) 2005-05-18
ATE295726T1 (de) 2005-06-15
HK1065706A1 (en) 2005-03-04
JP2006514937A (ja) 2006-05-18
ES2239196T3 (es) 2005-09-16
AU2003294718B2 (en) 2008-07-31
EP1567146A1 (de) 2005-08-31
PT1426049E (pt) 2005-09-30
CN100333723C (zh) 2007-08-29
RU2339372C2 (ru) 2008-11-27
CA2505040A1 (en) 2004-06-17
RU2008121750A (ru) 2009-12-20
ZA200503750B (en) 2006-11-29
NO20052959L (no) 2005-06-16
PL219696B1 (pl) 2015-06-30
CY1106256T1 (el) 2011-06-08
NZ540190A (en) 2007-03-30
US7632859B2 (en) 2009-12-15
BR0316947A (pt) 2005-10-18
HK1079108A1 (en) 2006-03-31
MXPA05005462A (es) 2005-07-25
SI1567146T1 (sl) 2007-02-28
DK1567146T3 (da) 2007-02-19

Similar Documents

Publication Publication Date Title
ATE342719T1 (de) Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE427762T1 (de) Vorlage zur behandlung von hamorrhoiden
ATE464863T1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
ATE531688T1 (de) Verbindungen zur modulation des rage-rezeptors
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
DE50006156D1 (de) Vorrichtung und verwendung zur steigerung der transdermalen permeation von arzneistoffen
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
SE0301663D0 (sv) Analysmetod för infusionsläkemedel
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
HUP0301119A2 (hu) Bioaktiváló hatóanyag és gyógyszerkészítmény
BR0308753A (pt) Método para produzir pseudo-ilhotas
RU2004113429A (ru) Способ лечения зрительного утомления у пользователей компьютерами
ATE428709T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60318423D1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
ATE291919T1 (de) Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
RU2002109173A (ru) Способ лечения дистрофических заболеваний сетчатой оболочки глаза
ATE395055T1 (de) Pharmazeutische zusammensetzung zur behandlung von hyperhomocysteinämie
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
JP2005161000A (ja) パターン湿布
RU2001129744A (ru) Способ лечения бациллярных форм туберкулеза легких
RU2001110285A (ru) Способ лечения хронического пиелонефрита

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567146

Country of ref document: EP

EEIH Change in the person of patent owner